Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Goodbody Health Inc on Friday reported a widened loss as the company experienced an expected decline in Covid testing during the first half of the year.
In the six months ended June 30, the Vancouver-based diagnostics firm widened its pretax loss to £1.4 million from £1.3 million the previous year.
Revenue jumped by 52% £7.4 million from £4.9 million. This was driven by its testing clinics, the company said.
Goodbody said, as expected, Covid testing declined in the half, impacting the interim results. However, the firm reassured that non-Covid testing continues to be rolled out to improve revenue by the end of 2022.
‘Growth in alternative testing has continued steadily although slower than as originally envisaged due to the current economic environment but we are still positive that due to the synergy of services with the NHS long term plan the final result will still be as per the original plan,’ commented Chair Geremy Thomas.
Shares in Goodbody Health are currently suspended on the AQSE Growth Market in London.
Copyright 2022 Alliance News Limited. All Rights Reserved.